科源制药
(301281)
| 流通市值：31.70亿 | | | 总市值：48.38亿 |
| 流通股本：7095.20万 | | | 总股本：1.08亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 363,604,662.98 | 359,077,870.81 | 74,832,571.09 | 265,178,915.25 |
| 交易性金融资产 | - | - | 251,910,842.48 | 103,287,552.83 |
| 应收票据及应收账款 | 187,052,979.87 | 105,657,550.41 | 96,148,335.76 | 97,025,326.87 |
| 其中：应收票据 | 12,234,886.81 | 9,565,437.94 | 4,705,152.98 | 5,232,632.31 |
| 应收账款 | 174,818,093.06 | 96,092,112.47 | 91,443,182.78 | 91,792,694.56 |
| 应收款项融资 | 11,078,029.99 | 12,316,963.95 | 3,744,072.46 | 5,042,191.97 |
| 预付款项 | 13,882,161.55 | 11,199,029.82 | 9,853,603.83 | 5,740,534.95 |
| 其他应收款合计 | 13,347,822.93 | 12,319,927.45 | 15,334,910.71 | 26,391,580.71 |
| 存货 | 141,478,364.21 | 147,446,770.78 | 151,084,601.64 | 147,478,076 |
| 其他流动资产 | 1,128,482.96 | 4,372,666.65 | 30,363,634.65 | 5,771,867.53 |
| 流动资产合计 | 731,572,504.49 | 652,390,779.87 | 633,272,572.62 | 655,916,046.11 |
| 非流动资产: | | | | |
| 长期股权投资 | 188,266,560.06 | 188,866,560 | 189,963,369.18 | 189,963,369.18 |
| 其他权益工具投资 | 2,651,414.32 | 2,651,414.32 | 2,651,414.32 | 2,651,414.32 |
| 固定资产 | 278,091,456.99 | 289,198,787.79 | 292,353,736.84 | 301,417,714.87 |
| 在建工程 | 405,240,027.95 | 390,164,728.76 | 276,678,711.52 | 251,754,028.56 |
| 无形资产 | 112,942,744.82 | 112,740,739.21 | 114,474,289.83 | 115,364,508.26 |
| 开发支出 | 810,000 | 2,619,433.96 | 2,619,433.96 | 1,809,433.96 |
| 商誉 | 1,025,455.1 | 1,025,455.1 | 1,820,994.04 | 1,820,994.04 |
| 长期待摊费用 | 1,795,880.84 | 965,960.88 | 407,701.7 | 435,384.52 |
| 递延所得税资产 | 4,343,201.19 | 4,261,719.99 | 3,337,100.31 | 3,302,549.08 |
| 其他非流动资产 | 64,056,740.43 | 42,779,449.9 | 88,266,978.88 | 79,910,162.03 |
| 非流动资产合计 | 1,059,223,481.7 | 1,035,274,249.91 | 972,573,730.58 | 948,429,558.82 |
| 资产总计 | 1,790,795,986.19 | 1,687,665,029.78 | 1,605,846,303.2 | 1,604,345,604.93 |
| 流动负债: | | | | |
| 短期借款 | 39,435,290.37 | - | - | - |
| 应付票据及应付账款 | 102,937,727.57 | 105,653,470.23 | 47,518,588.17 | 37,960,534.08 |
| 其中：应付票据 | 8,950,237.5 | 9,450,237.5 | 500,000 | - |
| 应付账款 | 93,987,490.07 | 96,203,232.73 | 47,018,588.17 | 37,960,534.08 |
| 合同负债 | 6,414,213.67 | 6,771,423.92 | 3,897,705.91 | 2,609,206.23 |
| 应付职工薪酬 | 12,911,087.8 | 12,428,932.49 | 12,682,645.78 | 12,097,856.04 |
| 应交税费 | 9,348,620.09 | 1,444,516.08 | 4,137,550.79 | 4,828,562.93 |
| 其他应付款合计 | 58,548,137.36 | 41,603,268.97 | 39,027,383.15 | 36,727,423.07 |
| 其他流动负债 | 10,079,535.95 | 8,085,680.35 | 5,283,433.24 | 5,843,941.27 |
| 流动负债合计 | 239,674,612.81 | 175,987,292.04 | 112,547,307.04 | 100,067,523.62 |
| 非流动负债: | | | | |
| 长期借款 | 117,147,993.16 | 112,344,762.56 | 97,578,953.28 | 95,801,027.98 |
| 预计负债 | 16,445,553.43 | 16,445,553.43 | - | - |
| 递延收益 | 7,862,108.6 | 8,412,118.31 | 9,152,895.76 | 9,893,673.22 |
| 递延所得税负债 | 16,270,860.89 | 18,293,556.62 | 15,119,841.81 | 16,480,838.34 |
| 非流动负债合计 | 157,726,516.08 | 155,495,990.92 | 121,851,690.85 | 122,175,539.54 |
| 负债合计 | 397,401,128.89 | 331,483,282.96 | 234,398,997.89 | 222,243,063.16 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 108,290,000 | 108,290,000 | 108,290,000 | 108,290,000 |
| 资本公积 | 912,796,880.18 | 907,682,874.3 | 907,672,976.25 | 907,672,976.25 |
| 专项储备 | 5,980,570.5 | 4,417,537.9 | 4,808,500.39 | 4,082,820.42 |
| 盈余公积 | 51,647,652.61 | 51,647,652.61 | 50,211,217.05 | 50,211,217.05 |
| 未分配利润 | 313,585,641.02 | 283,512,215.79 | 299,866,341.34 | 311,078,707.68 |
| 归属于母公司股东权益合计 | 1,392,300,744.31 | 1,355,550,280.6 | 1,370,849,035.03 | 1,381,335,721.4 |
| 少数股东权益 | 1,094,112.99 | 631,466.22 | 598,270.28 | 766,820.37 |
| 股东权益合计 | 1,393,394,857.3 | 1,356,181,746.82 | 1,371,447,305.31 | 1,382,102,541.77 |
| 负债和股东权益合计 | 1,790,795,986.19 | 1,687,665,029.78 | 1,605,846,303.2 | 1,604,345,604.93 |
| 公告日期 | 2026-04-24 | 2026-04-16 | 2025-10-24 | 2025-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |